Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (Iluvien®)

In a prospective real-world setting, Iluvien was associated with durable improvements in vision, macular anatomy, and QoL, with stable IOP. Treatment reduced the frequency of clinic visits and procedures, alleviating patient burden and caregiver absenteeism. These findings support Iluvien as a patient-centered, long-acting therapy for chronic DME and motivate multicenter validation and health-economic studies that incorporate caregiver outcomes.